STOCK TITAN

Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. director and CEO Ming Hsieh reported tax-related share dispositions rather than open-market sales. On March 1, 2026, 17,566 common shares at $15.33 per share were withheld to cover tax obligations from vested restricted stock units, leaving him with 900,634 directly held shares.

On February 26, 2026, a prior tax-withholding disposition of 2,949 shares at $24.76 per share left him with 918,200 directly held shares at that time. Indirect holdings as of that date include 7,895,115 shares held by the Dynasty Trust, 220,816 by The Ming Hsieh Trust, and 1,000-share positions in a Uniform Transfers to Minors Act account and an immediate family member’s account.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hsieh Ming

(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CA 91731

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 F 2,949(1) D $24.76 918,200 D
Common Stock 03/01/2026 F 17,566(2) D $15.33 900,634 D
Common Stock 7,895,115 I By Trust(3)
Common Stock 220,816 I By Trust(4)
Common Stock 1,000 I Uniform Transfer to Minor Account(5)
Common Stock 1,000 I By Immediate Family(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
3. Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.
4. Securities held by The Ming Hsieh Trust (the "Hsieh Trust"). Mr. Hsieh is the trustee of the Hsieh Trust and possesses the sole voting and dispositive power with respect to securities held by the Hsieh Trust.
5. Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.
6. Shares, which were previously held in a Uniform Transfers to Minor Act account, now held by an immediate family member residing in the same household as Ming Hsieh.
/s/ Paul Kim as Attorney-in-Fact 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for Ming Hsieh?

Ming Hsieh reported tax-related share withholdings, not open-market sales. Shares were withheld to satisfy tax obligations arising from vested restricted stock units granted in 2024 and 2025, consistent with standard equity compensation tax treatment.

How many Fulgent Genetics shares were withheld for Ming Hsieh’s taxes?

A total of 17,566 shares at $15.33 and 2,949 shares at $24.76 were withheld. These dispositions covered tax liabilities from restricted stock units that vested in 2024 and 2025, as described in the footnotes.

How many Fulgent Genetics shares does Ming Hsieh hold directly after these transactions?

After the March 1, 2026 tax-withholding disposition, Ming Hsieh directly holds 900,634 Fulgent Genetics common shares. This figure reflects shares remaining in his direct ownership following the most recent reported withholding event.

What indirect Fulgent Genetics (FLGT) holdings are associated with Ming Hsieh?

Indirect holdings include 7,895,115 shares in the Dynasty Trust, 220,816 shares in The Ming Hsieh Trust, and two 1,000-share positions via a Uniform Transfers to Minors Act account and an immediate family member’s account, as of February 26, 2026.

Are Ming Hsieh’s reported Fulgent Genetics transactions open-market sales?

The reported dispositions are not open-market sales. They are Code F transactions where shares were withheld to pay tax withholding obligations tied to vesting restricted stock units granted in February 2024 and February 2025.

What does transaction code F mean in Fulgent Genetics CEO’s Form 4?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this case, Fulgent Genetics shares were withheld from Ming Hsieh to cover tax withholding amounts on vested restricted stock units.
Fulgent Genetics

NASDAQ:FLGT

FLGT Rankings

FLGT Latest News

FLGT Latest SEC Filings

FLGT Stock Data

473.89M
20.81M
Diagnostics & Research
Services-medical Laboratories
Link
United States
EL MONTE